Navigation Links
Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
Date:3/19/2008

Diamyd Medical AB (http://www.omxgroup.com, OMX: DIAM B;

http://www.otcqx.com, OTC: DMYDY)

STOCKHOLM, Sweden, March 19 /PRNewswire-FirstCall/ -- Diamyd Medical (OMX: DIAM B)(OTC: DMYDY)announced today that the Swedish Medical Products Agency (MPA) has approved the Company's application to commence Phase III studies with the therapeutic diabetes vaccine Diamyd(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

"I am extremely glad that we now can offer our recently diagnosed type 1 diabetes patients the possibility to participate also in the European study," says Professor Johnny Ludvigsson, Linkoping, Sweden, Principal Investigator for the study.

Diabetes teams from approximately 20 Swedish pediatric clinics will meet in Linkoping, Sweden on April 4 to go through details for the study, which will comprise 306 new onset type 1 diabetes patients. Diamyd Medical is planning to file clinical trial applications in another 3-4 European countries and include additionally 20 clinics in the study.

"The approval from the Swedish MPA is another important step in the development of Diamyd(R) towards the market," says Elisabeth Lindner, President and CEO of Diamyd Medical. "Last week we received authorization from the FDA to start a parallel Phase III trial in the US, and together with TrialNet's planned study in the US, the interest in Diamyd is strong. We receive daily inquiries from parents of patients wanting to participate in our studies."

http://www.diamyd.com

Disclaimer: This document contains certain statements relating to the progress, timing and completion of our research, development and clinical trials. These statements can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Diamyd Medical undertakes no obligation to publicly update such statements, whether because of new information, future events or otherwise, nor does Diamyd Medical give any guarantees that the statements, given or implied, are correct. This document is a translation from the Swedish original. No guarantees are made that the translation is free from errors.


'/>"/>
SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
4. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
5. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
6. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
7. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
8. Gastric Banding Reverses Impact of Type 2 Diabetes
9. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
10. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
11. Help! Im Sick. How Do I Handle My Diabetes?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... of oral drug delivery systems, announced today that the Company ... Joseph Gunnar & Co. LLC, taking place on ... Nadav Kidron , CEO of Oramed, will present a ...   PIONEERS 2016, presented by Joseph Gunnar ...
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... --   , Total Sales ... Sales  Clinical sales grow 16% year-over-year  , ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... quarter ended March 31, 2016 and provided an update ... strategy. First Quarter 2016 Revenue Results by ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... It has just been ... keynote speaker for five events throughout the month of May. , Uldrich is the ... national news outlets. He also frequently appears on the Science Channel’s FutureScape and Discovery ...
(Date:5/2/2016)... ... May 02, 2016 , ... As directed by its board of directors during ... full support to allow certified nurse practitioners (CNP) to practice to the full scope ... such supervision for three years and 3,600 hours. , In addition, HAP supports CNPs ...
(Date:5/2/2016)... ... May 02, 2016 , ... Eating Recovery Center’s Insight ... mood and anxiety disorders, has rebranded its eating disorder program under a new name: ... disorder treatment facility on May 16. , To celebrate, ERC Chicago will host ...
(Date:5/2/2016)... ... May 02, 2016 , ... The ... the 2016 Main Residency Match® (“the Match”), the system through which U.S. and ... institutions. A record-high 30,750 positions were placed in the 2016 Match, and 29,572 ...
(Date:5/2/2016)... CA (PRWEB) , ... May 02, 2016 , ... East ... on dental extractions. Currently, patients can visit Dr. Assili to receive any dental extraction ... other offer, and it expires June 30, 2016. With the lower price, patients can ...
Breaking Medicine News(10 mins):